Published on NAVADHI Market Research (https://www.navadhi.com)

Home > Global Oncology Market Strategic Research Report 2026-2031

Global Oncology Market Strategic Research Report 2026-2031

Global Oncology Market Strategic Research Report 2026-2031
Publication ID: 
NAV0826014
Publication Date: 
August 24, 2026
Pages: 
328
Countries: 
Global [1]
Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

The global oncology market is undergoing a historic structural transformation driven by three simultaneous pharmaceutical supercycles - the immunotherapy/checkpoint inhibitor expansion, the antibody-drug conjugate (ADC) commercial wave, and the scaling of CAR-T and advanced cell therapies - collectively representing one of the most significant pharmaceutical market growth stories of the decade.

The market is estimated at USD 278.6 billion in 2025 - the base year - anchored to real, publicly disclosed FY2025 revenues from ten leading oncology pharmaceutical companies, and is forecast to reach USD 521.0 billion by 2031, a compound annual growth rate of approximately 11.0% across the 2025–2031 forecast period.

Targeted Therapy remains the largest segment by value, Immunotherapy/Checkpoint Inhibitors close behind and the fastest-growing established segment, while Antibody-Drug Conjugates represent the fastest-growing therapy category overall. North America leads regionally, with Asia-Pacific the fastest-growing region through 2031.

Scope of Global Oncology Market Strategic Research Report

  • This report covers the full spectrum of oncology therapeutics - pharmaceutical and biopharmaceutical products used in the treatment, prevention, and management of cancer - across all major global markets, with 2025 as the base year and forecasting to 2031.
  • This report provides segment by type (Targeted Therapy (Small Molecules), Immunotherapy / Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), CAR-T & Advanced Cell Therapies, Conventional Chemotherapy, Hormone / Endocrine Therapy, Radiopharmaceuticals & Radiation Oncology) forecast data by value for the global oncology market.
  • This report provides application segments (Lung Cancer (NSCLC & SCLC), Breast Cancer, Hematological Cancers (Blood/Lymphoma/MM), Colorectal Cancer, Prostate Cancer, Skin Cancer (Melanoma & NMSC), Gastric / Gastroesophageal Cancer, Ovarian, Cervical & Gynecologic Cancers, Bladder & Urologic Cancers, Other Solid Tumours & Rare Cancers) forecast data by value for the global oncology market.
  • This report provides region-wise (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) forecast data by value for the global oncology market.
  • This report also provides country-wise forecast data for the major markets across all five regions.
  • This report identifies key growth drivers and inhibitors (pain points) affecting the global oncology market.
  • This report provides company profiles including Company Overview, Key Products & Segments, Financial Performance, Business Strategy, and SWOT Analysis, along with competitive landscape for 328-page-detailed, verified companies in the global oncology market.
  • This report provides Porter's Five Forces analysis for the global oncology market.
  • This report provides PESTLE (Political, Economic, Social, Technological, Legal and Environmental) analysis for the global oncology market.
  • This report provides SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis for the global oncology market.
  • This report identifies key future trends in the global oncology market.

Segment by Type in Global Oncology Market Strategic Research Report

  • Targeted Therapy (Small Molecules)
  • Immunotherapy / Checkpoint Inhibitors
  • Antibody-Drug Conjugates (ADCs)
  • CAR-T & Advanced Cell Therapies
  • Conventional Chemotherapy
  • Hormone / Endocrine Therapy
  • Radiopharmaceuticals & Radiation Oncology

Segment by Application in Global Oncology Market Strategic Research Report

  • Lung Cancer (NSCLC & SCLC)
  • Breast Cancer
  • Hematological Cancers (Blood/Lymphoma/MM)
  • Colorectal Cancer
  • Prostate Cancer
  • Skin Cancer (Melanoma & NMSC)
  • Gastric / Gastroesophageal Cancer
  • Ovarian, Cervical & Gynecologic Cancers
  • Bladder & Urologic Cancers
  • Other Solid Tumours & Rare Cancers

Segment by Region in Global Oncology Market Strategic Research Report

  • North America
    • USA
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Australia
    • India
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Turkey
    • Egypt
    • South Africa
    • Rest of MEA

Who can use the Global Oncology Market Strategic Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the global oncology market. Some of the intended users for this report are:

  • C-level executives and Company Directors in pharmaceutical, biotechnology, and oncology healthcare companies
  • Industry consultants and Management consultants
  • Marketing professionals and Business development professionals
  • Investment managers, Financial professionals, and Venture Capitalists
  • Bank Managers, M&A Managers, and Auditors
  • Payers, Healthcare Policy Analysts, and Market Access professionals
  • Portfolio Managers and Equity Research Analysts covering oncology and pharmaceuticals
  • Anyone operating in the oncology drug value chain, from R&D through commercialization
  1. Executive Summary
    1. 1.1 Market Headline Metrics
    2. 1.2 Empirical Anchoring: Top-10 Company Revenue Base
    3. 1.3 The Three-Supercycle Growth Framework
    4. 1.3.1 Supercycle One: Immunotherapy Expansion and Combination Deepening
    5. 1.3.2 Supercycle Two: The ADC Commercial Wave
    6. 1.3.3 Supercycle Three: CAR-T and Advanced Cell Therapy Scaling
    7. 1.4 Segment Structure: Therapy Type and Market Positioning
    8. 1.5 Indication Landscape: Where Revenue Concentrates
    9. 1.6 Regional Structure and Growth Hierarchy
    10. 1.7 Strategic Implications and Report Objectives
  2. Industry Overview & Forecast
    1. 2.1 Global Oncology Market
    2. 2.2 The Three Supercycles Driving 11.0% CAGR
    3. 2.3 Overall Market Forecast 2025–2031
    4. 2.4 Methodology, Anchors, and Data Transparency
    5. 2.5 Segment Composition and Structural Shift
    6. 2.6 Cancer Indication Landscape
    7. 2.7 Regional Distribution and Growth Dynamics
    8. 2.8 Landmark Data Point: mRNA Neoantigen Cancer Vaccines
    9. 2.9 Summary Assessment
  3. Market Segmentation by Type
    1. 3.1 Overview of the Seven-Segment Framework
    2. 3.2 Targeted Therapy (Small Molecules)
    3. 3.3 Immunotherapy / Checkpoint Inhibitors
    4. 3.4 Antibody-Drug Conjugates (ADCs)
    5. 3.5 CAR-T and Advanced Cell Therapies
    6. 3.6 Conventional Chemotherapy
    7. 3.7 Hormone and Endocrine Therapy
    8. 3.8 Radiopharmaceuticals and Radiation Oncology
    9. 3.9 Cross-Segment Synthesis: Share Shift and Structural Implications
  4. Market Segmentation by Application
    1. 4.1 Overview of the Application Segmentation Framework
    2. 4.2 Lung Cancer (NSCLC and SCLC)
    3. 4.3 Breast Cancer
    4. 4.4 Hematological Cancers (Blood, Lymphoma, and Multiple Myeloma)
    5. 4.5 Colorectal Cancer
    6. 4.6 Prostate Cancer
    7. 4.7 Skin Cancer (Melanoma and Non-Melanoma Skin Cancer)
    8. 4.8 Gastric and Gastroesophageal Cancer
    9. 4.9 Ovarian, Cervical, and Gynecologic Cancers
    10. 4.10 Bladder and Urologic Cancers
    11. 4.11 Other Solid Tumours and Rare Cancers
    12. 4.12 Comparative Application Segment Growth Profile
    13. 4.13 Cross-Segment Analytical Observations
  5. Regional Market Forecast
    1. 5.1 North America
    2. 5.2 Europe
    3. 5.3 Asia-Pacific
    4. 5.4 Latin America
    5. 5.5 Middle East & Africa
  6. Country-Level Market Forecast
    1. 6.1 North America
    2. 6.1.1 USA
    3. 6.1.2 Canada
    4. 6.1.3 Rest N.America
    5. 6.2 Europe
    6. 6.2.1 Germany
    7. 6.2.2 France
    8. 6.2.3 UK
    9. 6.2.4 Italy
    10. 6.2.5 Spain
    11. 6.2.6 Switzerland
    12. 6.2.7 Rest Europe
    13. 6.3 Asia-Pacific
    14. 6.3.1 China
    15. 6.3.2 Japan
    16. 6.3.3 South Korea
    17. 6.3.4 Australia
    18. 6.3.5 India
    19. 6.3.6 Rest APAC
    20. 6.4 Latin America
    21. 6.4.1 Brazil
    22. 6.4.2 Mexico
    23. 6.4.3 Argentina
    24. 6.4.4 Colombia
    25. 6.4.5 Rest LatAm
    26. 6.5 Middle East & Africa
    27. Global Oncology Market Strategic Research Report 2026-2031
    28. 6.5.1 Saudi Arabia
    29. 6.5.2 UAE
    30. 6.5.3 Israel
    31. 6.5.4 Turkey
    32. 6.5.5 Egypt
    33. 6.5.6 South Africa
    34. 6.5.7 Rest MEA
  7. Growth Drivers & Inhibitors
    1. 7.1 Executive Summary of Force Dynamics
    2. 7.2 Growth Drivers
    3. 7.2.1 Pembrolizumab Label Expansion and the Broadening Checkpoint Inhibitor Paradigm
    4. 7.2.2 Antibody-Drug Conjugate Platform Acceleration
    5. 7.2.3 Targeted Therapy Volume Expansion into Adjuvant and Earlier Treatment Settings
    6. 7.2.4 CAR-T and Advanced Cell Therapy Commercial Scaling
    7. 7.2.5 Radiopharmaceutical Emergence as a Validated Commercial Platform
    8. 7.2.6 Asia-Pacific Market Expansion and Regulatory Modernisation
    9. 7.2.7 Demographic Tailwinds and Rising Global Cancer Incidence
    10. 7.3 Market Inhibitors
    11. 7.3.1 US Inflation Reduction Act Drug Price Negotiation
    12. 7.3.2 Biosimilar Penetration and Pricing Erosion in Maturing Segments
    13. 7.3.3 Manufacturing Complexity and CAR-T Access Constraints
    14. 7.3.4 European and Emerging Market Access and Reimbursement Barriers
    15. 7.3.5 Resistance Mechanisms and Durability Limitations in Targeted Therapy
    16. 7.3.6 Regulatory and Clinical Trial Execution Risk
    17. 7.4 Net Force Assessment
  8. Key Company Profiles
    1. 8.1 Merck & Co Inc.
    2. 8.1.1 Company Overview
    3. 8.1.2 Key Products & Segments
    4. 8.1.3 Financial Performance (2023–2025)
    5. 8.1.4 Business Strategy
    6. 8.1.5 SWOT Analysis
    7. 8.1.6 Strategic Implications (2025–2031)
    8. 8.2 Bristol-Myers Squibb
    9. 8.2.1 Company Overview
    10. 8.2.2 Key Products & Segments
    11. 8.2.3 Financial Performance (2023–2025)
    12. 8.2.4 Business Strategy
    13. 8.2.5 SWOT Analysis
    14. 8.2.6 Strategic Implications (2025–2031)
    15. 8.3 Roche Holding AG
    16. 8.3.1 Company Overview
    17. 8.3.2 Key Products & Segments
    18. 8.3.3 Financial Performance (2023–2025)
    19. 8.3.4 Business Strategy
    20. 8.3.5 SWOT Analysis
    21. 8.3.6 Strategic Implications (2025–2031)
    22. 8.4 AstraZeneca PLC
    23. 8.4.1 Company Overview
    24. 8.4.2 Key Products & Segments
    25. 8.4.3 Financial Performance (2023–2025)
    26. 8.4.4 Business Strategy
    27. 8.4.5 SWOT Analysis
    28. 8.4.6 Strategic Implications (2025–2031)
    29. 8.5 Johnson & Johnson
    30. Global Oncology Market Strategic Research Report 2026-2031
    31. 8.5.1 Company Overview
    32. 8.5.2 Key Products & Segments
    33. 8.5.3 Financial Performance (2023–2025)
    34. 8.5.4 Business Strategy
    35. 8.5.5 SWOT Analysis
    36. 8.5.6 Strategic Implications (2025–2031)
    37. 8.6 Pfizer Inc.
    38. 8.6.1 Company Overview
    39. 8.6.2 Key Products & Segments
    40. 8.6.3 Financial Performance (2023–2025)
    41. 8.6.4 Business Strategy
    42. 8.6.5 SWOT Analysis
    43. 8.6.6 Strategic Implications (2025–2031)
    44. 8.7 Novartis AG
    45. 8.7.1 Company Overview
    46. 8.7.2 Key Products & Segments
    47. 8.7.3 Financial Performance (2023–2025)
    48. 8.7.4 Business Strategy
    49. 8.7.5 SWOT Analysis
    50. 8.7.6 Strategic Implications (2025–2031)
    51. 8.8 AbbVie Inc.
    52. 8.8.1 Company Overview
    53. 8.8.2 Key Products & Segments
    54. 8.8.3 Financial Performance (2023–2025)
    55. 8.8.4 Business Strategy
    56. 8.8.5 SWOT Analysis
    57. 8.8.6 Strategic Implications (2025–2031)
    58. 8.9 Eli Lilly
    59. 8.9.1 Company Overview
    60. 8.9.2 Key Products & Segments
    61. 8.9.3 Financial Performance (2023–2025)
    62. 8.9.4 Business Strategy
    63. 8.9.5 SWOT Analysis
    64. 8.9.6 Strategic Implications (2025–2031)
    65. 8.10 Gilead Sciences
    66. 8.10.1 Company Overview
    67. 8.10.2 Key Products & Segments
    68. 8.10.3 Financial Performance (2023–2025)
    69. 8.10.4 Business Strategy
    70. 8.10.5 SWOT Analysis
    71. 8.10.6 Strategic Implications (2025–2031)
  9. Competitive Landscape
    1. 9.1 Competitive Landscape Overview
    2. 9.1.1 Top 5 Players — Estimated Oncology Revenue Market Share (FY2025)
    3. 9.1.2 Structural Dynamics Underpinning Competitive Intensity
    4. 9.2 Competitive Intensity Assessment
    5. 9.2.1 Tier Structure and Revenue Stratification
    6. 9.2.2 Capacity vs. Demand Dynamics
    7. 9.2.3 Pricing Environment
    8. 9.2.4 Barriers to Entry and Exit
    9. 9.3 Key Player Strategies & Positioning
    10. 9.4 Competitive Dynamics & Strategic Outlook
    11. 9.4.1 The Structural Architecture of Competition, 2025–2031
    12. 9.4.2 Emerging Competitive Threats
    13. 9.4.3 Consolidation vs. Fragmentation Outlook
    14. Global Oncology Market Strategic Research Report 2026-2031
    15. 9.4.4 Competitive Response Matrix
    16. 9.4.5 Strategic Recommendations for Market Participants, 2025–2031
    17. 9.4.6 Consolidation Outlook: 2025–2031
  10. Porter's Five Forces Analysis
    1. 10.1 Threat of New Entrants
    2. 10.2 Bargaining Power of Buyers
    3. 10.3 Bargaining Power of Suppliers
    4. 10.3.1 Key Factors
    5. 10.3.2 Market-Specific Context
    6. 10.3.3 Trend
    7. 10.3.4 Strategic Implication
    8. 10.4 Threat of Substitutes
    9. 10.4.1 Key Factors
    10. 10.4.2 Market-Specific Context
    11. 10.4.3 Trend
    12. 10.4.4 Strategic Implication
    13. 10.5 Competitive Rivalry
  11. PESTLE Analysis
    1. 11.1 Global Oncology Market — Strategic Macro-Environmental Assessment
    2. 11.2 Political
    3. 11.2.1 Government Oncology Prioritisation and National Cancer Strategies
    4. 11.2.2 Drug Pricing Legislation and Government Negotiation Authority
    5. 11.2.3 Geopolitical Fragmentation and Supply Chain Sovereignty
    6. 11.3 Economic
    7. 11.3.1 Macro-Financial Tailwinds Underpinning Market Expansion
    8. 11.3.2 Biopharmaceutical Financing Conditions and M&A Economics
    9. 11.3.3 Healthcare Budget Pressures and Access Economics
    10. 11.4 Social
    11. 11.4.1 Epidemiological Megatrend
    12. 11.4.2 Patient Empowerment, Advocacy, and Digital Health Literacy
    13. 11.4.3 Healthcare Workforce Constraints and Care Delivery Models
    14. 11.5 Technological
    15. 11.5.1 The ADC Technology Revolution
    16. 11.5.2 Artificial Intelligence and Multi-Omics in Drug Discovery
    17. 11.5.3 CAR-T Manufacturing Technology and Allogeneic Platforms
    18. 11.5.4 Biomarker Stratification and Companion Diagnostics
    19. 11.5.5 Radiopharmaceutical Technology Development
    20. 11.6 Legal
    21. 11.6.1 Intellectual Property Frameworks and Patent Cliff Dynamics
    22. 11.6.2 Regulatory Approval Frameworks
    23. 11.6.3 Clinical Trial Legal Frameworks and International Harmonisation
    24. 11.6.4 Liability, Pharmacovigilance, and Post-Market Safety Law
    25. 11.7 Environmental
    26. 11.7.1 Sustainability, ESG Commitments, and Pharmaceutical Manufacturing
    27. 11.7.2 Climate Change as a Health Burden Amplifier
    28. 11.7.3 Pharmaceutical Waste and Environmental Contamination
    29. 11.8 PESTLE Summary Assessment
  12. SWOT Analysis
    1. 12.1 Global Oncology Market Strategic Assessment
    2. 12.2 Overview and Methodology
    3. 12.3 Strengths
    4. 12.3.1 Unprecedented Commercial Scale and Revenue Momentum
    5. 12.3.2 Dominant Blockbuster Platform Anchors
    6. 12.3.3 Three Simultaneous Innovation Supercycles
    7. Global Oncology Market Strategic Research Report 2026-2031
    8. 12.3.4 Geographic Diversification and Emerging Market Optionality
    9. 12.3.5 Radiopharmaceuticals as a Validated Emerging Platform
    10. 12.4 Weaknesses
    11. 12.4.1 Manufacturing Complexity and Scalability Constraints
    12. 12.4.2 High Concentration Risk in a Small Number of Blockbusters
    13. 12.4.3 Affordability, Reimbursement, and Pricing Sustainability
    14. 12.4.4 Clinical and Regulatory Attrition in Late-Stage Pipelines
    15. 12.5 Opportunities
    16. 12.5.1 Indication Expansion and First-Line Migration of Established Products
    17. 12.5.2 Allogeneic CAR-T: From Niche to Mainstream
    18. 12.5.3 Asia-Pacific Market Development and NMPA Acceleration
    19. 12.5.4 Radiopharmaceutical Pipeline Expansion
    20. 12.5.5 Biomarker-Driven Precision Medicine and Companion Diagnostics
    21. 12.5.6 Combination Regimen Innovation
    22. 12.6 Threats
    23. 12.6.1 Keytruda Patent Cliff and Biosimilar Entry Risk
    24. 12.6.2 Drug Pricing Regulation and Government Reimbursement Intervention
    25. 12.6.3 Competitive Intensity and Therapy Category Disruption
    26. 12.6.4 China-US Geopolitical and Supply Chain Risk
    27. 12.6.5 Clinical Pipeline Failure and Late-Stage Trial Risk
    28. 12.6.6 Macroeconomic Pressures and Healthcare Budget Constraints
    29. 12.7 Strategic Synthesis
  13. Future Trends & Outlook
    1. 13.1 Executive Outlook Summary
    2. 13.2 Therapeutic Modality Trajectories
    3. 13.2.1 Immunotherapy: From Expansion to Optimisation
    4. 13.2.2 Antibody-Drug Conjugates: The Highest-Conviction Growth Segment
    5. 13.2.3 CAR-T and Advanced Cell Therapies: Scaling Toward Mainstream
    6. 13.2.4 Radiopharmaceuticals: Platform Validation and Pipeline Depth
    7. 13.3 Pipeline Productivity and Regulatory Environment
    8. 13.3.1 NDA/BLA Filing Volume and Regulatory Throughput
    9. 13.3.2 Biomarker-Driven Label Expansion
    10. 13.4 Combination Regimen Convergence
    11. 13.4.1 The IO + ADC Combination Paradigm
    12. 13.4.2 Targeted Therapy + IO and Bispecific Antibody Platforms
    13. 13.5 Manufacturing, Access, and Economics
    14. 13.5.1 Cost-of-Goods Trajectory and Margin Implications
    15. 13.5.2 Pricing, Reimbursement, and Access Dynamics
    16. 13.6 Geographic Market Development
    17. 13.6.1 Asia-Pacific: The Decisive Growth Geography
    18. 13.6.2 North America: Continued Dominance with Structural Adjustment
    19. 13.6.3 Europe: Value-Based Framework Adaptation
    20. 13.7 Competitive Landscape Dynamics
    21. 13.7.1 Consolidation and Pipeline Acquisition
    22. 13.7.2 Biosimilar and Generic Competitive Pressure
    23. 13.8 Disruptive Risk Factors and Scenario

List of Exhibits

  • Exhibit 3.1  Global Oncology Market — Overall Forecast 2026–2031 (USD Billion)
  • Exhibit 3.2  Key Forecast Dynamics — Global Oncology Market 2025–2031
  • Exhibit 3.3  Market Segment Share by Therapy Type — Global Oncology Forecast 2025 (IN %)
  • Exhibit 3.4  Market Segment Share by Therapy Type — Global Oncology Forecast 2031 (IN %)
  • Exhibit 3.5  Targeted Therapy (Small Molecules) Market Forecast 2025-2031in USD Billion
  • Exhibit 3.6  Immunotherapy / Checkpoint Inhibitors Market Forecast 2025-2031in USD Billion
  • Exhibit 3.7  Antibody-Drug Conjugates (ADCs) Market Forecast 2025-2031in USD Billion
  • Exhibit 3.8  CAR-T & Advanced Cell Therapies Market Forecast 2025-2031in USD Billion
  • Exhibit 3.9  Conventional Chemotherapy Market Forecast 2025-2031in USD Billion
  • Exhibit 3.10 Hormone / Endocrine Therapy Market Forecast 2025-2031in USD Billion
  • Exhibit 3.11 Radiopharmaceuticals & Radiation Market Forecast 2025-2031in USD Billion
  • Exhibit 3.12 YoY ONCOLOGY MARKET CAGR GROWTH BY SEGMENT (%) - 2026-31
  • Exhibit 3.13 Segment-Level Forecast — by Cancer Indication
  • Exhibit 3.14 Global Oncology Market Application by Market Share in % in 2025
  • Exhibit 3.15 Global Oncology Market Application by Market Share in % in 2031
  • Exhibit 3.16 Lung Cancer (NSCLC & SCLC) Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.17 Breast Cancer Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.18 Hematological Cancers (Blood/Lymphoma/MM) Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.19 Colorectal Cancer Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.20 Prostate Cancer Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.21 Skin Cancer (Melanoma & NMSC) Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.22 Gastric / Gastroesophageal Cancer Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.23 Ovarian, Cervical & Gynecologic Market Forecast 2025-2031 in USD billion
  • Exhibit 3.24 Bladder & Urologic Cancers Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.25 Other Solid Tumours & Rare Cancers Market Forecast 2025-2031in USD Billion
  • Exhibit 3.26 Region-wise Oncology Market Share 2025 in %
  • Exhibit 3.27 Region-wise Oncology Market Share 2031 in %
  • Exhibit 3.28 Region-wise Oncology Market CAGR Growth 2025-2031 in %
  • Exhibit 3.29 North America Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.30 Europe Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.31 APAC Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.32 Latin America Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.33 Middle East & Africa Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.34 USA Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.35 Canada Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.36 Rest of America Canada Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.37 China Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.38 Japan Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.39 India Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.40 South Korea Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.41 Australia Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.42 Rest of APAC Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.43 Germany Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.44 France Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.45 UK Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.46 Italy Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.47 Spain Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.48 Switzerland Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.49 Rest of Europe Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.50 Brazil Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.51 Mexico Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.52 Argentina Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.53 Colombia Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.54 Rest of Latin America Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.55 Saudi Arabia Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.56 UAE Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.57 Israel Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.58 Turkey Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.59 Egypt Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.60 South Africa Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 3.61 Rest of MEA Oncology Market Forecast 2025-2031 in USD Billion
  • Exhibit 6.1 Porter’s Five Forces Analysis of Global Oncology Market
  • Exhibit 7.1 Key Players in Global Oncology Market – Competitive Landscape
  • Exhibit 7.2 SWOT Analysis — Merck & Co Inc.
  • Exhibit 7.3 SWOT Analysis — Bristol-Myers Squibb
  • Exhibit 7.4 SWOT Analysis — AstraZeneca PLC
  • Exhibit 7.5 SWOT Analysis — Roche Holding AG
  • Exhibit 7.6 SWOT Analysis — Johnson & Johnson Source
  • Exhibit 7.7 SWOT Analysis — Pfizer Inc.
  • Exhibit 7.8 SWOT Analysis — Novartis AG
  • Exhibit 7.9 SWOT Analysis — AbbVie Inc.
  • Exhibit 7.10 SWOT Analysis — Eli Lilly and Company
  • Exhibit 7.11 SWOT Analysis — Gilead Sciences Inc.
  • Exhibit 9.1 SWOT Analysis of Global Oncology Market

Merck & Co Inc., Bristol-Myers Squibb, Roche Holding AG, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc.

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Enterprise license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Enterprise license fee.

 

Enterprise License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

About Us

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Source URL:https://www.navadhi.com/publications/global-oncology-market-strategic-research-report-2026-2031

Links
[1] https://www.navadhi.com/countries/global